老年晚期非小细胞肺癌的化疗可行性

The feasibility of chemotherapy in the elderly with advanced non-small cell lung cancer

目的 通过分析比较去甲长春花碱 (NVB)联合顺铂 (DDP)治疗老年和中青年非小细胞肺癌(NSCLC)患者的疗效和毒性 ,探讨老年患者化疗的可行性。方法 回顾性将我院 1994年 6月～ 1999年 12月收治的以NVB联合DDP治疗的 139例晚期NSCLC患者按中国年龄段划分标准分为老年组 (年龄≥ 6 0岁 )和中青年组 (年龄 <6 0岁 ) ,比较两组的疗效和毒性。结果 老年组和中青年组的有效率、中位生存期分别为 38.2 %、12个月和 38.1%、9个月 ;两组的III～IV血色素、白细胞、血小板下降分别为 9.1%、5 6 .4 %、5 .5 %和 4 .8%、5 9.5 %、2 .4 % ,差异均无显著性。结论 一般状况良好 (KPS≥ 80 )的老年患者能够耐受中等剂量化疗。

Objective To explore the feasibility of chemotherapy in the elderly patients by analysing the effects and toxicities between the old and young patients with advanced non\|small cell lung cancer (NSCLC) treated by novelbin and cisplatin.Methods A retrospective survey was conducted in 139 patients suffered from advanced NSCLC treated with novelbin and cisplatin.The patients were divided into two groups by age:group A≥60 and group B<60.The effects and toxicities between the two groups were compared. Results The response rate and median survival in group A and group B were 38.2%,12 months and 38.1%,9 months respectively;Grade 3～4 anemia,neutropenia,thrombocytopenia were 9.1%, 56.4%, 5.5% and 4.8%,59.5%,2.4% respectively.There was no significant statistical difference between the two groups.Conclusion Moderate\|dose chemotherapy would be well\|tolerated by elderly patients with Karnofsky≥80.